Illumina: Unlocking the Power of Genome
pharmatechoutlook

Pharma Tech Outlook: Pharma Tech Magazine

Illumina: Unlocking the Power of Genome

Follow Illumina on :

Francis deSouza, CEO, IlluminaFrancis deSouza, CEO
The exponential expansion of the genomics realm comes with increased complexities that demand the application of mission-critical, innovative technologies and groundbreaking assays to genetic variation and function analysis. In line with these growing needs, Illumina was founded with a mission to improve human health by enabling researchers and scientists with a better understanding of genetic variation at all the levels of complexities.

A developer, manufacturer, and marketer of integrated systems for analysis of genetic variation and biological function, Illumina provides a comprehensive line of products and services that help researchers to explore DNA at an entirely new scale. These products and services assist genomic research centers, pharmaceutical companies, academic institutions, and biotechnology companies in sequencing, genotyping and marking gene expression. From genetic health, food safety to cancer research, Illumina’s breakthrough solutions enable researchers to select the best solution for their scientific challenge.

Standing at the intersection of biology and technology, Illumina has designed leading-edge, simple, more accessible, and reliable sequencing and array-based solutions that mitigate the scale of experimentation and functional analysis to advance disease research, drug development, and the development of molecular tests. The extensive range of solutions and services include sequencing platforms to sequence DNA and RNA, microarray scanners to screen tools for analyzing genetic variation, next-generation sequencing (NGS) to study biological system, and BaseSpace Informatics Suite to remove common informatics barriers.

Illumina provides a sequencing technology that enables researchers to perform a wide variety of applications and study biological system. NGS delivers information that was beyond the capacity of traditional DNA sequencing technologies to researchers.
The platform allows the researchers to expediently sequence whole genomes, vastly explore the deep sequence target regions, analyze epigenetic factors such as genome-wide DNA methylation and DNA-protein interactions, and much more. NGS has the capability to deliver exceptional data quality and accuracy, at the scale that its clients’ needs.

iSeq 100 provides robustness and dependability for a broad range of applications ranging from germline and somatic tumor categorizing to 16S microbial analysis and targeted gene expression

Illumina’s sequencing enables a wide variety of sequencing reagents, the iSeq 100 Sequencing System, in particular, makes a more accessible and affordable NSG, as it allows labs of all sizes to sequence DNA and RNA feasibly. Harnessing the speed and affordability of complementary metal-oxide-semiconductor (CMOS) technology and the accuracy of sequencing by synthesis (SBS) chemistry, the iSeq 100 System enables virtually any lab to acquire powerful next-generation sequencing (NGS) technology. “The iSeq 100 provides robustness and dependability for a broad range of applications ranging from germline and somatic tumor categorizing to 16S microbial analysis and targeted gene expression,” says Francis deSouza, President and CEO at Illumina.

To meet diverse research needs, Illumina is developing microarrays for surveying thousands of samples to identify point mutations, structural variants, or changes in gene expression and methylation. Powered by Infinium technology, Illumina microarrays aid the researchers with genetic variant detection straight from discovery applications to routine screening. Illumina microarrays offer several advantages over other microarrays as it provides trusted data quality and built-in lab management, tracking, and traceability tools. These microarrays help detect the chromosomal alterations and copy number variation and also integrate with Illumina sequencing systems for multi-omics analyses.

Illumina finds a unique place in the industry by placing a high value on collaborative interactions for rapid delivery of solutions. Illumina will continue its endeavor to make their solutions increasingly simple enabling their clients to read and understand genetic variations efficiently. With the ability to sequence at an unprecedented scale, the company aims to trigger a fundamental shift in the healthcare realm, meanwhile transforming human health.
Share this Article:

Company
Illumina

Headquarters
San Diego, CA

Management
Francis deSouza, CEO

Description
Illumina applies innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for Illumina to deliver innovative, flexible, and scalable solutions to meet the needs of their customers. As a global company that places a high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, Illumina strives to meet this challenge. Illumina's innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics

Illumina News

ArcherDX Announces Partnership with Illumina to Develop In-Vitro Diagnostic Tests

BOULDER, Colo: ArcherDX, Inc., a growth-stage molecular diagnostics company dedicated to developing breakthrough solutions that advance personalized genomic medicine, announced a non-exclusive partnership with Illumina, Inc. (NASDAQ: ILMN) to develop in-vitro diagnostic (IVD) tests for Archer's planned portfolio of next-generation sequencing (NGS)-based companion diagnostics.

The scope of the agreement includes ArcherDX's future portfolio of IVD tests used to facilitate targeted therapy selection and monitoring of Minimal Residual Disease for the management of patients with solid tumor and blood cancers. The planned IVD tests will empower commercial laboratories, hospitals and health systems to run these assays in their local laboratories worldwide.

Under the agreement, ArcherDX will develop IVD tests to run on Illumina's NextSeq™ 550Dx System. ArcherDX will be responsible for obtaining necessary regulatory approvals for each IVD kit and for their subsequent commercialization. ArcherDX and Illumina entered into a similar agreement for the MiSeq™ Dx System in 2016.

"We are pleased to expand our development partnership with Illumina, whose large install base and highly accurate sequencing systems will accelerate our efforts to democratize access to high-quality genomic testing by developing distributable diagnostic assays that can be used to identify targeted therapy options, as well as monitor for the recurrence of disease across a wide variety of cancers," said Jason Myers, Chief Executive Officer and co-founder of ArcherDX. "These IVD tests will provide important new options for providers and patients around the world."

"Partnerships that bring exceptional clinical content to customers and patients represent an exciting opportunity in clinical genomics," said Dr. Phil Febbo, Chief Medical Officer of Illumina. "By enabling ArcherDX to develop IVD tests, we are ensuring health care providers and patients have access to a growing menu of important distributable diagnostic tests that will improve patient outcomes."

QIAGEN and Illumina Partner to Deliver Sequencing-Based In-Vitro Diagnostic (IVD) Tests

San Diego, California, Hilden, Germany and Germantown, Maryland: Illumina, Inc. (NASDAQ: ILMN) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced a 15-year partnership intended to broaden the availability and use of NGS-based in-vitro diagnostic (IVD) kits, including companion diagnostics, for patient management.

The agreement grants QIAGEN non-exclusive rights to develop and globally commercialize IVD kits to be used together with Illumina’s MiSeq™ Dx and NextSeq™ 550Dx Systems. The agreement also includes rights for expansion of the partnership on future Illumina diagnostic (Dx) systems. Both partners are also exploring opportunities for QIAGEN to develop and market companion diagnostics based on Illumina’s TruSight Oncology (TSO) assays that enable comprehensive genomic profiling of tumor samples in immunotherapy.

Illumina and QIAGEN will cooperate to commercialize a menu of clinically validated workflows that combine QIAGEN’s proprietary content and bioinformatics solutions. The partnership will initially focus on commercializing oncology IVD kits to support patient management and may expand in the future to include additional clinical diagnostic fields, such as cardiology, hereditary diseases, infectious diseases, as well as inflammatory and autoimmune diseases.

“We are committed to expanding the range of clinical use cases addressed by genomic sequencing by enabling partners to deliver IVD tests and companion diagnostics on Illumina’s Dx instruments,” said Francis deSouza, CEO of Illumina. “Our partnership with QIAGEN will complement Illumina’s TSO 500 family with additional testing menu options, accelerating NGS adoption in oncology patient management.”

“Bringing together our highly complementary capabilities marks an important milestone to advance the use of NGS technologies in clinical decision-making and our shared vision of using this powerful technology to improve the outcomes for patients worldwide,” said Peer M. Schatz, Chief Executive Officer of QIAGEN. “We at QIAGEN are very pleased with this ground-breaking partnership and this first step in what we hope to be a long and productive relationship that capitalizes on combining our unique strengths. This partnership becomes a key cornerstone of our NGS strategy, which continues to include our universal solutions for use with any sequencer as well as the GeneReader NGS System for use primarily with smaller, targeted gene panels. Through this partnership, we look forward to creating significant benefits for customers and for both parties, as well as to allowing QIAGEN to maximize our opportunities as a company creating value by offering sample-to-insight solutions.”

Bringing together highly complementary capabilities

Through this partnership, QIAGEN endeavors to build a broad menu of IVD tests on Illumina’s Dx sequencers by leveraging its market leading companion diagnostic capabilities and Sample to Insight solutions, thereby enhancing both companies’ channel reach and presence in the IVD market.

QIAGEN is an established global leader in molecular (PCR and NGS-driven) precision medicine given its portfolio of more than 25 master collaboration agreements with pharmaceutical and biotechnology companies to co-develop and gain regulatory approvals for companion diagnostics. So far, seven therapies have received FDA co-approval with a QIAGEN companion diagnostic assay.

With global availability of the MiSeq Dx and NextSeq 550Dx platforms, Illumina has a robust diagnostic NGS product portfolio capable of covering a broad range of clinical applications designed for a variety of clinical lab settings. As NGS testing begins to play a more significant role in patient care, Illumina is committed to providing clinical solutions, both Illumina developed and partner driven, that support the diagnosis and management of human diseases.